Premium
Isolation of Human B‐Cell Subpopulations for Pharmacological Studies
Author(s) -
Bauer Johann,
Stünkel Klaus G. E
Publication year - 1991
Publication title -
biotechnology progress
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.572
H-Index - 129
eISSN - 1520-6033
pISSN - 8756-7938
DOI - 10.1021/bp00011a002
Subject(s) - antibody , b cell , biology , in vivo , in vitro , microbiology and biotechnology , glycolipid , immunology , biochemistry
Three groups of human peripheral blood B‐lymphocytes were separated from each other by countercurrent centrifugal elutriation and free‐flow electrophoresis. They differed in their state of maturation and in their capability to produce antibodies in vitro. These B‐cell subpopulations were used to study features of a drug such as BAY R 1005. BAY R 1005 is a synthetic glycolipid analogue (GLA), which is supposed to modulate antibody synthesis. Mature, immunoglobulin‐(Ig‐) secreting B‐lymphocytes secreted equal quantities of antibodies in the presence and in the absence of the GLA. BAY R 1005 was found to be without mitogenic activity on resting B‐cells and did not induce them to produce antibodies. However, it supported the antibody production of preactivated B‐lymphocytes. The in vitro preactivated B‐cells were affected via monocytes. Only in vivo preactivated B‐lymphocytes increased their antibody production under the direct influence of BAY R 1005.